drugset / Trial / NCT05349435

A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate

NCT05349435

Phase 1 Terminated 8 enrolled Liminal BioSciences Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the safety, tolerability and pharmacokinetic profile of fezagepras (PBI-4050) to that of sodium phenylbutyrate (PBA) when both products are given as single ascending doses to healthy adult subjects.

Timeline

Start
2022-05-13
Primary completion
2022-06-30
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SETOGEPRAM Small molecule
Subject Sodium Phenylbutyrate Small molecule